Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2007 Jan;56(1):e1-54. Epub 2006 Nov 7.

Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).

Author information

  • 1Washington University, St. Louis, Missouri, USA.

Abstract

The introduction of a number of biologic therapies into the market has revolutionized the practice of dermatology. These therapies include interferons, intravenous immunoglobulin, infliximab, adalimumab, etanercept, efalizumab, alefacept, and rituximab. Most dermatologists are familiar with the Food and Drug Administration-approved indications of these medications. However, numerous off-label uses have evolved. As part 1 of a 2-part series, this article will review the literature regarding the off-label uses of the interferons and intravenous immunoglobulin in dermatology.

PMID:
17190617
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk